



Multiple Myeloma (MM)

What is multiple myeloma?


Multiple myeloma (MM) is an incurable cancer which arises from plasma cells in bone marrow.¹



In a healthy immune system, some white blood cells (B-cells) are activated to become plasma cells, which secrete antibodies in response to infection.²



In multiple myeloma, abnormal plasma cells (myeloma cells) build up in the bone marrow and form tumours in many bones of the body.³



These tumors may keep the bone marrow from making enough healthy blood cells, and can damage and weaken the bone.³

Signs and symptoms


Patients with MM may experience a variety of disease-related symptoms, including:⁴



A persistent dull ache in their bones, commonly affecting areas such as the back, ribs or hips



Fatigue (caused by anaemia)




Repeated infections

These symptoms can have physical and emotional impacts on the quality of life of people who live with MM.^{5,6}

Prevalence and patients



In Europe, approximately **77,000 people** are living with MM.⁷




Affects **4 in 100,000** people worldwide each year.⁸

Classified as an **Orphan Disease** in Europe and the US.⁹



Most common in people over **65 years**.¹⁰



Affects slightly more **men** than women.¹⁰

29%

of patients don't survive >1 year after diagnosis.¹¹




People impacted by blood cancer need more than treatment and care. To improve awareness and further support patients and their families, Janssen has launched 'Make Blood Cancer Visible' - a campaign to get people talking about blood cancers and bring forward patient perspectives.

#LETSTALKABOUTBLOODCANCER

visit www.facebook.com/letstalkaboutbloodcancer

Multiple Myeloma (MM)

Prognosis¹²



- There is currently no cure available, so even when patients go into remission relapse is inevitable.¹
- Patients live in fear of these relapses, which typically become more aggressive, leading to the development of treatment-resistant disease.¹⁴
- Patients who relapse after treatment with standard therapies have poor prognoses and few effective treatment options available.^{12,15}

Treatment

While treatments have improved MM remains an incredibly complex disease to treat, especially as patients can become resistant to treatment.¹⁴

More can still be done to improve outcomes for patients including addressing these areas of unmet medical need:¹⁶

- Improved efficacy
- Reduced side effects
- Longer periods of remission



References

- 1 Abdi J, Chen G, Chang H, et al. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms *Oncotarget*. 2013;4:2186–207.
- 2 American Cancer Society. About multiple myeloma. Available at: <https://www.cancer.org/content/dam/CRC/PDF/Public/8738.00.pdf> Last accessed June 2017.
- 3 National Cancer Institute. Plasma Cell Neoplasms (Includint Multiple Myeloma) Treatment (PDQ®) - Patient version. Available at: <https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq> Last accessed June 2017.
- 4 NHS Choices. Multiple myeloma: symptoms. Available at: <http://www.nhs.uk/Conditions/Multiple-myeloma/Pages/Symptoms.aspx> Last accessed June 2017.
- 5 Comert M, Gunes AE, Sahin F, Saydam G. Quality of life and supportive care in multiple myeloma. *Turk J Hematol*. 2013;30:234–46.
- 6 Hameed A, Brady JJ, Dowling P, et al. Bone disease in multiple myeloma: pathophysiology and management. *Cancer Growth Metastasis*. 2014;7:33–42.
- 7 GLOBOCAN 2012. Estimated cancer incidence and prevalence: European Union (EU-28). Available at: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx Last accessed June 2017.
- 8 Kyle RA, Rajkumar SV. Multiple myeloma. *Blood*. 2008;111:2962–72.
- 9 Aronson JK. Rare diseases and orphan drugs. *Br J Clin Pharmacol*. 2006;61:243–5.
- 10 American Cancer Society. Multiple myeloma: causes, risk factors, and prevention. Available at: <https://www.cancer.org/content/dam/CRC/PDF/Public/8739.00.pdf> Last Accessed June 2017.
- 11 Costa LJ, Gonsalves WL, Kumar SK. Early mortality in multiple myeloma. *Leukemia*. 2015;29:1616–8.
- 12 Kurtin SE. Relapsed or Relapsed/Refractory Multiple Myeloma. *J Adv Pract Oncol* 2013;4(Suppl 1):5–14.
- 13 Anderson KC, Kyle RA, Rajkumar SV, et al. Clinically relevant end points and new drug approvals for myeloma. *Leukemia*. 2008;22(2):231–9.
- 14 Dimopoulos MA, Richardson PG, Moreau P, Anderson KC. Current treatment landscape for relapsed and/or refractory multiple myeloma. *Nat Rev Clin Oncol*. 2015;12:42–54.
- 15 Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. *Leukemia*. 2012;26:149–57.
- 16 Richardson PG, Palumbo A, Mateos MV, et al. The current unmet medical needs in the treatment and management of multiple myeloma (MM). *Clin Lymphoma Myeloma Leuk*. 2015;15(Suppl.3):e244 (abstract PO-288).



People impacted by blood cancer need more than treatment and care. To improve awareness and further support patients and their families, Janssen has launched 'Make Blood Cancer Visible' - a campaign to get people talking about blood cancers and bring forward patient perspectives.

#LETSTALKABOUTBLOODCANCER

visit www.facebook.com/letstalkaboutbloodcancer